Cervical cancer: camrelizumab plus apatinib shows promising response

  • Lan C & al.
  • J Clin Oncol
  • 14 Oct 2020

  • curated by Deepa Koli
  • Univadis Clinical Summaries
Access to the full content of this site is available only to registered healthcare professionals. Access to the full content of this site is available only to registered healthcare professionals.

Takeaway

  • Camrelizumab plus apatinib shows good response and manageable toxicities in previously treated patients with advanced cervical cancer.

Why this matters

  • The activity of camrelizumab plus apatinib was superior to that reported for anti-programmed cell death protein 1/programmed death-ligand 1 (PD-L1) antibody or vascular endothelial growth factor pathway inhibitor monotherapy alone.

Study design

  • Multicenter, phase 2 CLAP trial.
  • 45 patients with advanced cervical cancer (median age, 51.0 years), who progressed after ≥1 line of systemic therapy, received camrelizumab plus apatinib.
  • Funding: Chinese National Natural Science Foundation project.

Key results

  • Median follow-up was 11.3 months.
  • Objective response rate (ORR) was 55.6% (complete responses, 4.4%; partial responses, 51.1%).
  • Median PFS was 8.8 months (95% CI, 5.6 months to not estimable).
  • Median duration of response and median OS were not reached.
  • Treatment-related grade 3/4 adverse event rate was 71.1%; most common were hypertension (24.4%), anemia (20.0%), and fatigue (15.6%).
  • 33.3% of patients experienced potential immune-related toxicities; most common was hypothyroidism (22.2%).
  • No difference in ORR was observed between patients with PD-L1-positive and PD-L1-negative tumors (69.0% vs 50.0%; P=.281).
Limitations
  • Open label, single group.